NOS2 and neoplasm: Although the difference between iNOS+ PMN-MDSCs depleted groups and undepleted groups or L-NIL treated group and untreated groups were not statistically different, we observed a trend that suggested a potential therapeutic benefit by MDSCs’ high iNOS activity on tumor regression.